Text Size

Omidenepag Isopropyl Versus Timolol in Patients With Glaucoma or Ocular Hypertension: Two Randomized Phase 3 Trials (SPECTRUM 4 and 3)

Bacharach J., Brubaker J.W., Evans D.G., LU F., Odani-Kawabata N., Yamabe T., Wirta D.L.


  • 2024
  • American Journal of Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    From the North Bay Eye Associates (J.B.), Petaluma, CA, United States; Sacramento Eye Consultants (J.W.B.), Sacramento, CA, United States; Total Eye Care, P.A.(D.G.E.), Memphis, TN, United States; Santen, Inc.(F.L., T.Y.), Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd (N.O.-K., T.Y.), Osaka, Japan; Eye Research Foundation (D.L.W.), Newport Beach, CA, United States

Related Publications

Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.


24-Hour Evaluation of the Effectiveness and Tolerability of Preservative-Free Tafluprost-Timolol Fixed Combination in Open-Angle Glaucoma or Ocular Hypertensive Patients Previously Treated with Preserved Latanoprost

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM


MicroRNA profile of extracellular vesicles released by Müller glial cells

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022